6:29 PM
 | 
Sep 18, 2013
 |  BC Extra  |  Company News

FDA accepts Epanova NDA

AstraZeneca plc (LSE:AZN; NYSE:AZN) said FDA accepted an NDA for Epanova to treat severe hypertriglyceridemia, defined...

Read the full 70 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >